
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is poised for success with their robust pipeline, particularly with the potential for accelerated approval of AMT-130 and their partnership with Bristol Myers Squibb. However, clinical and regulatory risks must be taken into account and their heavy reliance on the success of AMT-130 poses a potential risk to their business. Additionally, competition in the market and challenges with marketing and commercialization may impact their success. A price target of $37 is based on probability-adjusted modeling of key franchises, with a DCF valuation and WACC of 11.2%.
Bears say
uniQure is a relatively young company with limited revenue streams and high research and development costs, resulting in negative earnings. The success of their pipeline products is uncertain, and any setbacks could have a significant impact on their financials. Additionally, their partnership with Bristol Myers Squibb for cardiovascular diseases may not provide meaningful revenue in the near term. These factors add to the overall risk profile of the company, leading to a negative outlook on their stock.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares